BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its holdings in Eli Lilly And Co (NYSE:LLY) by 27.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 262,086 shares of the company’s stock after selling 101,167 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Eli Lilly And Co were worth $28,124,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of LLY. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Eli Lilly And Co in the second quarter worth about $114,000. Fort L.P. acquired a new stake in Eli Lilly And Co during the second quarter worth about $121,000. Welch Group LLC acquired a new stake in Eli Lilly And Co during the third quarter worth about $123,000. Zions Bancorporation acquired a new stake in Eli Lilly And Co during the third quarter worth about $128,000. Finally, Twin Tree Management LP grew its position in Eli Lilly And Co by 97.9% during the second quarter. Twin Tree Management LP now owns 1,589 shares of the company’s stock worth $136,000 after buying an additional 786 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.
NYSE LLY opened at $118.64 on Monday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. The company has a market cap of $125.68 billion, a price-to-earnings ratio of 22.09, a P/E/G ratio of 1.85 and a beta of 0.31. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $118.71.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s payout ratio is 52.57%.
A number of equities research analysts recently weighed in on the company. Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research report on Monday, November 26th. Credit Suisse Group raised Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research report on Wednesday, October 31st. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. JPMorgan Chase & Co. set a $123.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Friday, October 5th. Finally, Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Thursday, September 27th. Nine equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Buy” and an average target price of $111.24.
In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 6,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total transaction of $637,860.00. Following the sale, the senior vice president now directly owns 55,224 shares of the company’s stock, valued at $5,870,863.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the sale, the insider now directly owns 3,148,647 shares in the company, valued at $44,081,058. The disclosure for this sale can be found here. Insiders have sold 2,127,900 shares of company stock worth $167,037,195 over the last ninety days. Company insiders own 0.11% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/12/03/eli-lilly-and-co-lly-stake-lowered-by-british-columbia-investment-management-corp.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What are defining characteristics of a correction?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.